Ackman forewarns Allergan
at Investor's Business Daily - Tue Sep 23, 5:45PM CDT
William Ackman of Pershing Square Capital Management wrote a letter to Allergan's (AGN)board saying that a deal with Salix Pharmaceuticals (SLXP), which would not have to be approved by shareholders if it's all cash, could be a breach of fiduciary...
Progenics' Azedra Found Positive in Phase II Follow-Up Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 5:10PM CDT
Progenics Pharmaceuticals, Inc. (PGNX) reported positive data from a long-term follow-up pivotal phase II study on its ultra-orphan radio-therapeutic candidate, Azedra, in patients suffering from malignant pheochromocytoma.
Stocks Finish Lower Among Takeover Rumors
at Investor's Business Daily - Tue Sep 23, 5:06PM CDT
Stocks finished the day down moderately, with the Nasdaq and the S&P 500 lower for the third straight day. Volume was running lighter than the previous day, according to preliminary figures. The Nasdaq was down 0.4%; the S&P 500 fell 0.6% and the Dow...
Salix Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 5.84%
Comtex SmarTrend(R) - Tue Sep 23, 3:40PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $165.16 to a high of $170.71. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $165.32 on volume of 5.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Carmax and Medtronic are big market movers
AP - Tue Sep 23, 3:22PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Burger King, THI Deal in Focus as U.S. Curbs Tax Inversions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 2:05PM CDT
Burger King Worldwide, Inc. (BKW) and Tim Hortons proposed merger deal is focus with the Obama administration taking several actions to curb tax inversion deals.
Stocks Fall To Session Lows; Vipshop Bucks The Trend
at Investor's Business Daily - Tue Sep 23, 2:00PM CDT
Selling picked up the pace in the major averages in late-afternoon trading Tuesday. The Dow Jones industrial average fell 0.6%; the S&P 500 gave up 0.4% and the Nasdaq lost 0.3%. NYSE and Nasdaq volume was tracking about 5% to 10% lower than Monday's...
Stocks Fall Modestly; New Issue Alibaba Extends Losses
at Investor's Business Daily - Tue Sep 23, 10:56AM CDT
Major averages opened lower and stayed there about two hours into Tuesday's session. Losses were mild, though, on a busy day of headline flow. The Dow Jones industrial average lost 0.3%; the S&P 500 fell 0.2% and the Nasdaq eased less than 0.1%. NYSE...
Video: Allergan-Ackman War Reignites On Salix Rumors
at Investor's Business Daily - Tue Sep 23, 10:47AM CDT
Salix Pharmaceuticals jumped 6% to a new high above 169 on the stock market today on news that fellow specialty drugmaker Allergan is probably about to buy it. However, one of Allergan's largest shareholders threatened to sue if the two companies...
Indexes Pare Losses As Salix Soars On Buyout Talk
at Investor's Business Daily - Tue Sep 23, 9:56AM CDT
Major averages pared some of their early losses and were mixed in late-morning trading as investors weighed mixed economic reports from China, Europe and the U.S., as well as U.S. airstrikes in Syria. The Nasdaq was up 0.1%, while the S&P 500 was...
Results of Clinical Trials, New Drug Applications, Leadership Appointments, and Scheduled Earnings - Research Reports on Biogen, Salix, Express Scripts, Stryker and Shire
PR Newswire - Tue Sep 23, 8:25AM CDT
Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Express Scripts Holding Company (NASDAQ: ESRX), Stryker Corporation (NYSE: SYK) and Shire plc. (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6674-100free.
Stock Futures Lower, But Salix Soars On Buyout Talk
at Investor's Business Daily - Tue Sep 23, 7:55AM CDT
The stock market today was set to open lower after mixed economic reports from China and Europe, and as the U.S. and Arab nations began airstrikes in Syria against the Islamic State. Nasdaq, S&P 500 and Dow Jones industrial average futures were down...
September 23 Premarket Briefing: 10 Things You Should Know
at The Street - Tue Sep 23, 5:54AM CDT
U.S. stock futures point lower; the U.S. clamps down on corporate inversions; Allergan in advanced talks to buy Salix; Facebook to unveil a new advertising platform.
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
Salix' s Xifaxan 550 sNDA Under Review, Response by Feb 28 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Sep 19, 5:10PM CDT
Salix (SLXP) is looking to expand the use of Xifaxan 550 for the treatment of irritable bowel syndrome with diarrhea.
Salix acquires additional intellectual property for rifaximin for reduction in risk of overt hepatic encephalopathy recurrence
M2 - Fri Sep 19, 6:16AM CDT
Salix Pharmaceuticals (NasdaqGS:SLXP) reported on Thursday the receipt of exclusive rights under certain patent applications in the "Rifaximin Complexes" patent family from Cipla.
Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN(R) 550mg sNDA for Treatment of Irritable Bowel Syndrome with Diarrhea
Business Wire - Thu Sep 18, 12:42PM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) considers the Company's August 29, 2014 resubmission of its supplemental New Drug Application (sNDA) for XIFAXAN(R)550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D to be complete. The resubmission is considered a class 2 response to the FDA's March 7, 2011 action letter and has been assigned a user fee goal date of February 28, 2015.
Salix Secures Additional Intellectual Property Relating to Rifaximin
Business Wire - Thu Sep 18, 6:30AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Cipla Limited has granted Salix exclusive rights under certain patent applications in the "Rifaximin Complexes" patent family controlled by Cipla. The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa. Additionally, Salix and Cipla have expanded the scope of their 2009 exclusive license agreement whereby Cipla granted Salix exclusive rights in the United States, Canada and Mexico under certain patent rights covering amorphous rifaximin. By means of this amendment to the 2009 agreement, the rights already licensed to Salix in the United States, Canada and Mexico are expanded to include certain patent rights in the European Union, Japan, Australia, New Zealand and South Korea. Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the "Rifaximin Complexes" patent rights. Salix also will pay royalties on net sales of products covered by the "Rifaximin Complexes" patents licensed to Salix.
AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 3:45PM CDT
AstraZeneca (AZN) announced that the FDA has cleared Movantik for use in adults with chronic non-cancer pain suffering from opioid-induced constipation.
3 Stocks Pushing The Health Care Sector Higher
at The Street - Wed Sep 17, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.